ClinicalTrials.gg
CompletedNCT00370331RAISEUpdated Apr 18, 2017Results posted

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag

A Phase 3 interventional study of eltrombopag and Placebo in Purpura, Thrombocytopaenic, Idiopathic, sponsored by GlaxoSmithKline. Completed at 115 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-18.

Primary conditionPurpura, Thrombocytopenic, IdiopathicRegistry: PurpuraReclassifiedWhy we changed it
Registry
Purpura — the first condition term the registry derived for this study.
ClinicalTrials.gg
Purpura, Thrombocytopenic, Idiopathic
Why
  1. The study's title name Purpura, Thrombocytopenic, Idiopathic, a narrower term within Purpura.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
197
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
3rd of 36
197 · median 40
Started
2006
with 1 other
Phase 3
9 of 36
none open now
Registered
3rd of 36
by date
Lead sponsor
9 of 36
GlaxoSmithKline

Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 3rd largest by enrollment, is one of 2 that started in 2006, is one of 9 in phase 3, and was the 3rd registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

The rationale for this Phase III study is to evaluate the 6 month safety and efficacy of eltrombopag in the treatment of previously treated subjects with chronic ITP. The starting dose of eltrombopag, 50 mg, once daily was selected based upon the observed efficacy, safety and pharmacokinetics in a dose-finding Study (TRA100773). This Phase III study is a randomized, double-blind, placebo-controlled, Phase III study, to evaluate efficacy, safety and tolerability of eltrombopag, initially administered as 50 mg oral tablets once daily for six months in adult subjects with previously treated chronic ITP. Subjects will be randomized 2:1, eltrombopag to placebo, and will be stratified based upon splenectomy status, use of ITP medication at baseline and baseline platelet count less than or equal to 15,000/µL. Subjects will receive study medication for 6 months, during which the dose of study medication may be adjusted based upon individual platelet counts. In addition, subjects may taper off concomitant ITP medications and may receive any rescue treatments as dictated by local standard of care. After discontinuation of study medication, subjects will complete follow-up visits at weeks 1, 2, 4 and months 3 and 6.

Read the detailed description

A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administered for 6 months as oral tablets once daily in adult subjects with previously treated chronic idiopathic thrombocytopenic purpura (ITP).

03

Conditions studied

  • Purpura, Thrombocytopaenic, Idiopathic

Browse trials for

Keywords

  • ITP
  • idiopathic
  • platelets
  • purpura
  • thrombocytopenia
  • Idiopathic Thrombocytopenic Purpura
  • thrombocytopenic
04

In context

Purpura, Thrombocytopenic, Idiopathic Reclassified

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

This study's enrollment of 197 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Purpura, Thrombocytopenic, Idiopathic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Purpura. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A subject will be eligible for inclusion in this study only if all of the following criteria apply:
  • Subject has signed and dated a written .
  • Adults (≥18 years) diagnosed with chronic ITP according to the American Society for Hematology/British Committee for Standards in Hematology (ASH/BCSH) guidelines [George, 1996; BCSH, 2003], and count \< 30,000/μL on Day 1 (or within 24 hours prior to dosing on Day 1). In addition, a peripheral blood smear should support the diagnosis of ITP with no evidence of other causes of thrombocytopenia (e.g. pseudothrombocytopenia, myelofibrosis). The physical examination should not suggest any disease which may cause thrombocytopenia other than ITP.
  • Subjects who have previously received one or more prior ITP therapies. Previous treatments for ITP include but are not limited to , immunoglobulins, azathioprine, danazol, cyclophosphamide and/or rituximab.
  • Subjects must have either initially responded (platelet count > 100,000/μL) to a previous ITP therapy or have had a bone marrow examination consistent with ITP within 3 years to rule out myelodysplastic syndromes or other causes of thrombocytopenia.
  • Previous therapy for ITP with immunoglobulins (IVIg and anti-D) must have been completed at least 1 week prior to randomization and the platelet count must show a clear downward trend after the last treatment with immunoglobulins. Previous treatment for ITP with splenectomy, rituximab and cyclophosphamide must have been completed at least 4 weeks prior to randomization, or clearly be ineffective.
  • Subjects treated with concomitant ITP medication (e.g. corticosteroids or azathioprine) must be receiving a dose that has been stable for at least 4 weeks prior to randomization. Subjects treated with cyclosporine A, mycophenolate mofetil or danazol must be receiving a dose that has been stable for at least 3 months prior to randomization. The medication should be continued with a stable dose for the initial 6 weeks of study "Concomitant ITP Therapy")
  • (PT/INR) and activated partial thromboplastin time (aPTT) must be within 80 to 120% of the normal range with no history of hypercoagulable state.
  • A complete blood count (CBC), within the reference range (including WBC differential not indicative of a disorder other than ITP), with the following exceptions:
  • \< 30,000 platelets/μL on Day 1 (or within 24 hours of Day 1) is required for inclusion,
  • : Subjects with hemoglobin levels between 10 g/dL (100 g/L) and the lower limit of normal are eligible for inclusion, if anemia is clearly attributable to ITP (excessive blood loss).
  • ≥ 1500/μL (1.5 x 10\^9/L) is required for inclusion (elevated WBC/ANC due to steroid treatment is acceptable).
  • The following clinical chemistries MUST NOT exceed the (ULN) reference range by more than 20%: creatinine, , AST, total , and alkaline phosphatase. In addition, total albumin must not be below the lower limit of normal (LLN) by more than 10%.
  • Subject is practicing an acceptable method of (documented in chart). Female subjects (or female partners of male subjects) must either be of non- (hysterectomy, bilateral oophorectomy, bilateral tubal ligation or > 1 year), or of childbearing potential and use one of the following highly effective methods of contraception (i.e., Pearl Index \<1.0%) from two weeks prior to administration of study medication, throughout the study, and 28 days after completion or premature discontinuation from the study:
  • Complete abstinence from intercourse;
  • Intrauterine device (IUD);
  • Two forms of barrier contraception (diaphragm plus spermicide, and for males condom plus spermicide);
  • Male partner is sterile prior to entry into the study and is the only partner of the female;
  • Systemic contraceptives (combined or progesterone only). Subject is able to understand and comply with protocol requirements and instructions and intends to complete the study as planned.

Exclusion criteria

Exclusion criteria:

  • A subject will NOT be eligible for inclusion in this study if any of the following criteria apply:
  • Any abnormality, other than ITP, identified on the screening examination or any other medical condition or circumstance, which in the opinion of the investigator makes the subject unsuitable for participation in the study or suggests another primary diagnosis (e.g., thrombocytopenia is secondary to another disease).
  • Concurrent malignant disease and/or history of cancer treatment with cytotoxic chemotherapy and/or radiotherapy.
  • Any prior history of arterial or venous thrombosis (stroke, , myocardial infarction, deep vein thrombosis or pulmonary embolism), AND ≥ two of the following risk factors: hormone replacement therapy, systemic (containing estrogen), smoking, diabetes, hypercholesterolemia, medication for hypertension, cancer, hereditary thrombophilic disorders (e.g., Factor V Leiden, ATIII deficiency, etc), or any other family history of arterial or venous thrombosis.
  • Pre-existing cardiovascular disease (congestive heart failure, [NYHA] Grade III/IV), or arrhythmia known to increase the risk of thromboembolic events (e.g. atrial fibrillation), or subjects with a >450 msec.
  • Female subjects who are nursing or pregnant (positive serum or urine b-human chorionic gonadotrophin pregnancy test) at screening or pre-dose on Day 1.
  • History of alcohol/drug abuse.
  • Treatment with an drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication.
  • Subject treated with drugs that affect function (including but not limited to aspirin, clopidogrel and/or NSAIDs) or anti-coagulants for > 3 consecutive days within 2 weeks of the study start and until the end of the study.
  • History of platelet agglutination abnormality that prevents reliable measurement of platelet counts.
  • All subjects with secondary immune thrombocytopenia, including those with laboratory or clinical evidence of infection, anti-phospholipid antibody syndrome, chronic infection, virus infection, or any evidence for active hepatitis at the time of subject screening. If a potential subject has no clinical history that would support HIV infection or hepatitis infection, no further laboratory screening is necessary; however, standard medical practice would suggest further evaluation of patients who have risk factors for these infections.
  • Previous participation in a clinical study with eltrombopag.
  • Patients planning to have cataract surgery.
  • In France, a subject is neither affiliated with nor a beneficiary of a social security category.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
197 participants (actual)

Study arms

  • Experimental
    Treatment arm plus standard of care

    Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.

    Drug: eltrombopag

  • Placebo comparator
    placebo plus standard of care

    Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.

    Drug: Placebo

Interventions

  • Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.

  • DrugPlacebo

    Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down

07

What researchers measure

Primary outcomes

  1. Percentage of Responders

    The percentage of evaluable participants who achieved a platelet response (defined as a platelet count between 50,000 and 400,000 microliter) at each nominal on-therapy day and 4 weeks post-treatment

    Time frame: Baseline; each on-therapy treatment day; Weeks 10, 14, 18, 22, and 26; and Weeks 1, 2, and 4 post-treatment

Secondary outcomes

  1. Summary of Median Platelet Counts

    Platelet counts were measured by blood draw.

    Time frame: Baseline; Day 8 through Week 26 on-treatment; and 1, 2, 4 week follow-up visits

  2. Percentage of Participants Initiating Rescue Treatment On-therapy

    Percentage of participants initiating new ITP medication, an increased dose of concomitant ITP medication from baseline, platelet transfusion, or splenectomy.

    Time frame: Anytime from Day 1 to Week 26

  3. Maximum and Total Weeks of Platelet Response

    Response is defined as a platelet count between 50,000 and 400,000 platelets per microliter.

    Time frame: Day 1 through Week 26 on-treatment

  4. Percentage of Participants With a Reduction in Use of Baseline ITP Medication

    Percentage of participants who experienced a reduction in their baseline concomitant ITP medication use

    Time frame: From Day 1 through Week 26 on-treatment

  5. WHO Bleeding Scale

    Summary of World Health Organization (WHO) bleeding scores at each nominal visit. WHO Grades 1-4 = any bleeding; WHO Grades 2-4 = clinically significant bleeding

    Time frame: Baseline, all nominal visits on-therapy defined as Day 8, Day 15, Day 22, Day 29, Day 36, Day 43, Week 10, Week 14, Week 18, Week 22, Week 26, and 1, 2 and 4 week follow-up visits

  6. HR-QoL Instrument and Domain Scores From the SF-36v2 Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment

    Health-related quality of life (HR-QoL) patient reported outcomes from the short form-36v2 (SF-36v2) questionnaire. Scores could range from 0 (worst possible) to 100 (best possible).

    Time frame: Baseline, Week 6, Week 14, and Week 26/Early Withdrawal

  7. HR-QoL Instrument and Domain Scores From the FACIT-F Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment

    Health-related quality of life (HR-QoL) patient reported outcomes from the functional assessment of chronic illness therapy fatigue (FACIT-F) questionnaire. Scores could range from 0 (worst possible) to 52 (best possible).

    Time frame: Baseline, Week 6, Week 14, and Week 26/Early Withdrawal

  8. HR-QoL Instrument and Domain Scores for the FACT-Th Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment

    Health-related quality of life (HR-QoL) patient reported outcomes from the functional assessment of cancer therapy thrombocytopenia (FACT-Th) questionnaire (six selected items). Scores could range from 0 (worst possible) to 24 (best possible).

    Time frame: Baseline, Week 6, Week 14, and Week 26/Early Withdrawal

  9. HR-QoL Instrument and Domain Scores From the MEI-SF Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment

    Health-related quality of life (HR-QoL) patient reported outcomes from the motivation and energy inventory-short form (MEI-SF) questionnaire. Scores could range from 0 (worst possible) to 72 (best possible).

    Time frame: Baseline, Week 6, Week 14, and Week 26/Early Withdrawal

08

Results

Posted Feb 23, 2010

Participant flow

Participant flow — Overall Study
MilestonePlaceboEltrombopag 50 mg QD
Started62135
Completed55112
Not completed723
Withdrew: Adverse event413
Withdrew: Withdrawal by subject24
Withdrew: Lost to follow-up03
Withdrew: Lack of efficacy01
Withdrew: Non-compliance01
Withdrew: Protocol violation11

Outcome measures

PrimaryPercentage of Responders

The percentage of evaluable participants who achieved a platelet response (defined as a platelet count between 50,000 and 400,000 microliter) at each nominal on-therapy day and 4 weeks post-treatment

Time frame:
Baseline; each on-therapy treatment day; Weeks 10, 14, 18, 22, and 26; and Weeks 1, 2, and 4 post-treatment
Reported as:
Number · Percentage of participants
Percentage of Responders
Percentage of participantsPlaceboEltrombopag 50 mg QD
Baseline21
Day 8737
Day 15846
Day 22851
Day 291049
Day 36856
Day 431454
Week 101752
Week 141846
Week 181746
Week 221949
Week 261752
1 Week Follow-up1542
2 Week Follow-up1822
4 Week Follow-up1420
Statistical analysis
  • Placebo vs Eltrombopag 50 mg QD · Repeated measures model for binary data · p = <0.001 · Odds ratio (or): 8.2 · 99% CI 3.59 to 18.73Repeated measures model for binary data using Generalized Estimating Equations (GEE)
SecondarySummary of Median Platelet Counts

Platelet counts were measured by blood draw.

Time frame:
Baseline; Day 8 through Week 26 on-treatment; and 1, 2, 4 week follow-up visits
Reported as:
Median · platelets/microliter (ul)
Summary of Median Platelet Counts
platelets/microliter (ul)PlaceboEltrombopag 50 mg QD
Baseline16,000 (2000 to 87,000)16,000 (0 to 78,000)
Day 817,500 (3000 to 354,000)36,000 (1000 to 593,000)
Day 1518,000 (2000 to 214,000)54,000 (2000 to 750,000)
Day 2218,500 (1000 to 271,000)54,000 (1000 to 507,000)
Day 2918,000 (3000 to 313,000)53,000 (1000 to 400,000)
Day 3619,000 (4000 to 297,000)60,000 (1000 to 952,000)
Day 4320,000 (3000 to 275,000)59,000 (1000 to 545,000)
Week 1020,000 (0 to 293,000)61,500 (1000 to 433,000)
Week 1417,500 (1000 to 303,000)60,000 (1000 to 409,000)
Week 1820,500 (2000 to 281,000)61,000 (3000 to 363,000)
Week 2223,000 (1000 to 315,000)72,000 (3000 to 408,000)
Week 2623,000 (2000 to 315,000)73,500 (1000 to 429,000)
1 Week Follow-up19,000 (0 to 323,000)38,500 (1000 to 409,000)
2 Week Follow-up18,000 (1000 to 340,000)21,000 (1000 to 434,000)
4 Week Follow-up18,000 (1000 to 301,000)24,000 (1000 to 446,000)
SecondaryPercentage of Participants Initiating Rescue Treatment On-therapy

Percentage of participants initiating new ITP medication, an increased dose of concomitant ITP medication from baseline, platelet transfusion, or splenectomy.

Time frame:
Anytime from Day 1 to Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants Initiating Rescue Treatment On-therapy
Percentage of participantsPlaceboEltrombopag 50 mg QD
Participants who received rescue treatment4018
Participants who did not receive rescue treatment6082
SecondaryMaximum and Total Weeks of Platelet Response

Response is defined as a platelet count between 50,000 and 400,000 platelets per microliter.

Time frame:
Day 1 through Week 26 on-treatment
Reported as:
Median · Weeks
Maximum and Total Weeks of Platelet Response
WeeksPlaceboEltrombopag 50 mg QD
Maximum continuous Response0 (0 to 25)8.1 (0 to 26)
Cumulative Response0 (0 to 25)10.9 (0 to 26)
SecondaryPercentage of Participants With a Reduction in Use of Baseline ITP Medication

Percentage of participants who experienced a reduction in their baseline concomitant ITP medication use

Time frame:
From Day 1 through Week 26 on-treatment
Reported as:
Number · Percentage of participants
Percentage of Participants With a Reduction in Use of Baseline ITP Medication
Percentage of participantsPlaceboEltrombopag 50 mg QD
Participants who reduced/discontinued ITP therapy3259
Participants not reducing/discont. ITP therapy6841
SecondaryWHO Bleeding Scale

Summary of World Health Organization (WHO) bleeding scores at each nominal visit. WHO Grades 1-4 = any bleeding; WHO Grades 2-4 = clinically significant bleeding

Time frame:
Baseline, all nominal visits on-therapy defined as Day 8, Day 15, Day 22, Day 29, Day 36, Day 43, Week 10, Week 14, Week 18, Week 22, Week 26, and 1, 2 and 4 week follow-up visits
Reported as:
Number · Percentage of participants
WHO Bleeding Scale
Percentage of participantsPlaceboEltrombopag 50 mg QD
Baseline, WHO Grades 1-47773
Day 8, WHO Grades 1-47356
Day 15, WHO Grades 1-46839
Day 22, WHO Grades 1-46738
Day 29, WHO Grades 1-45637
Day 36, WHO Grades 1-46623
Day 43, WHO Grades 1-45923
Week 10, WHO Grades 1-44922
Week 14, WHO Grades 1-45723
Week 18, WHO Grades 1-45922
Week 22, WHO Grades 1-44618
Week 26, WHO Grades 1-45622
1 Week Follow-up, WHO Grades 1-45928
2 Week Follow-up, WHO Grades 1-45650
4 Week Follow-up, WHO Grades 1-45946
Baseline, WHO Grades 2-42822
Day 8, WHO Grades 2-42016
Day 15, WHO Grades 2-4228
Day 22, WHO Grades 2-42111
Day 29, WHO Grades 2-41910
Day 36, WHO Grades 2-4197
Day 43, WHO Grades 2-4195
Week 10, WHO Grades 2-4139
Week 14, WHO Grades 2-4175
Week 18, WHO Grades 2-4182
Week 22, WHO Grades 2-4108
Week 26, WHO Grades 2-4157
1 Week Follow-up, WHO Grades 2-42011
2 Week Follow-up, WHO Grades 2-41816
4 Week Follow-up, WHO Grades 2-42113
SecondaryHR-QoL Instrument and Domain Scores From the SF-36v2 Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment

Health-related quality of life (HR-QoL) patient reported outcomes from the short form-36v2 (SF-36v2) questionnaire. Scores could range from 0 (worst possible) to 100 (best possible).

Time frame:
Baseline, Week 6, Week 14, and Week 26/Early Withdrawal
Reported as:
Mean · Points on a scale (0-100)
HR-QoL Instrument and Domain Scores From the SF-36v2 Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment
Points on a scale (0-100)PlaceboEltrombopag 50 mg QD
SF-36v2 physical function, Baseline75.0 ± 21.773.1 ± 26.8
SF-36v2 physical function, Week 676.5 ± 20.878.0 ± 24.4
SF-36v2 physical function, Week 1477.6 ± 20.078.9 ± 22.5
SF-36v2 physical funct., Week 26/Early Withdrawal75.8 ± 22.680.6 ± 21.7
SF-36v2 physical role, Baseline64.5 ± 26.764.5 ± 30.5
SF-36v2 physical role, Week 666.9 ± 25.473.7 ± 27.4
SF-36v2 physical role, Week 1467.2 ± 25.872.9 ± 24.9
SF-36v2 physical role, Week 26/Early Withdrawal67.5 ± 27.173.7 ± 25.4
SF-36v2 bodily pain, Baseline70.0 ± 23.275.2 ± 27.8
SF-36v2 bodily pain, Week 669.9 ± 25.978.5 ± 25.4
SF-36v2 bodily pain, Week 1468.3 ± 24.877.6 ± 25.8
SF-36v2 bodily pain, Week 26/Early Withdrawal68.5 ± 25.075.7 ± 26.6
SF-36v2 general health, Baseline53.7 ± 21.856.0 ± 21.3
SF-36v2 general health, Week 655.9 ± 21.459.7 ± 21.5
SF-36v2 general health, Week 1452.8 ± 23.259.3 ± 20.7
SF-36v2 general health, Week 26/Early Withdrawal53.3 ± 24.957.3 ± 23.1
SF-36v2 vitality, Baseline56.7 ± 20.255.1 ± 26.3
SF-36v2 vitality, Week 659.0 ± 20.062.1 ± 22.7
SF-36v2 vitality, Week 1456.8 ± 22.361.0 ± 22.4
SF-36v2 vitality, Week 26/Early Withdrawal57.5 ± 22.460.0 ± 23.3
SF-36v2 social function, Baseline76.1 ± 21.772.7 ± 28.3
SF-36v2 social function, Week 678.0 ± 21.477.6 ± 26.2
SF-36v2 social function, Week 1473.4 ± 25.878.4 ± 22.6
SF-36v2 social function, Week 26/Early Withdrawal75.0 ± 25.879.0 ± 24.2
SF-36v2 emotional role, Baseline73.4 ± 25.469.1 ± 30.9
SF-36v2 emotional role, Week 673.1 ± 24.677.5 ± 25.9
SF-36v2 emotional role, Week 1473.3 ± 22.974.1 ± 25.2
SF-36v2 emotional role, Week 26/Early Withdrawal71.5 ± 26.576.9 ± 25.4
SF-36v2 mental health, Baseline70.3 ± 18.768.0 ± 21.0
SF-36v2 mental health, Week 671.7 ± 18.371.8 ± 19.0
SF-36v2 mental health, Week 1468.6 ± 20.470.6 ± 19.3
SF-36v2 mental health, Week 26/Early Withdrawal68.6 ± 22.870.2 ± 21.6
SF-36v physical component summary, Baseline45.6 ± 8.346.9 ± 9.7
SF-36v physical component summary, Week 646.2 ± 8.348.7 ± 9.0
SF-36v physical component summary, Week 1446.3 ± 8.349.0 ± 8.1
SF-36v physical component summary, Week 26/EW46.2 ± 8.148.7 ± 8.6
SF-36v2 mental component summary, Baseline46.4 ± 10.144.3 ± 12.6
SF-36v2 mental component summary, Week 646.8 ± 10.047.2 ± 11.1
SF-36v2 mental component summary, Week 1445.3 ± 11.146.2 ± 11.3
SF-36v2 mental component summary, Week 26/EW45.2 ± 12.346.5 ± 12.4
SecondaryHR-QoL Instrument and Domain Scores From the FACIT-F Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment

Health-related quality of life (HR-QoL) patient reported outcomes from the functional assessment of chronic illness therapy fatigue (FACIT-F) questionnaire. Scores could range from 0 (worst possible) to 52 (best possible).

Time frame:
Baseline, Week 6, Week 14, and Week 26/Early Withdrawal
Reported as:
Mean · Points on a scale (0-52)
HR-QoL Instrument and Domain Scores From the FACIT-F Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment
Points on a scale (0-52)PlaceboEltrombopag 50 mg QD
Baseline36.3 ± 9.036.0 ± 12.2
Week 638.3 ± 8.239.2 ± 9.7
Week 1436.9 ± 10.239.5 ± 9.9
Week 26/Early Withdrawal37.0 ± 11.339.2 ± 10.1
SecondaryHR-QoL Instrument and Domain Scores for the FACT-Th Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment

Health-related quality of life (HR-QoL) patient reported outcomes from the functional assessment of cancer therapy thrombocytopenia (FACT-Th) questionnaire (six selected items). Scores could range from 0 (worst possible) to 24 (best possible).

Time frame:
Baseline, Week 6, Week 14, and Week 26/Early Withdrawal
Reported as:
Mean · Points on a scale (0-24)
HR-QoL Instrument and Domain Scores for the FACT-Th Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment
Points on a scale (0-24)PlaceboEltrombopag 50 mg QD
Baseline14.8 ± 5.813.5 ± 5.8
Week 615.1 ± 5.715.9 ± 6.0
Week 1415.3 ± 5.416.7 ± 5.6
Week 26/Early Withdrawal15.3 ± 6.016.0 ± 6.1
SecondaryHR-QoL Instrument and Domain Scores From the MEI-SF Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment

Health-related quality of life (HR-QoL) patient reported outcomes from the motivation and energy inventory-short form (MEI-SF) questionnaire. Scores could range from 0 (worst possible) to 72 (best possible).

Time frame:
Baseline, Week 6, Week 14, and Week 26/Early Withdrawal
Reported as:
Mean · Points on a scale (0-72)
HR-QoL Instrument and Domain Scores From the MEI-SF Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment
Points on a scale (0-72)PlaceboEltrombopag 50 mg QD
Baseline71.3 ± 17.272.7 ± 21.4
Week 673.4 ± 16.476.2 ± 19.5
Week 1471.1 ± 20.576.9 ± 20.5
Week 26/Early Withdrawal72.0 ± 21.776.7 ± 20.2

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—11/61 (18%)56/61 (91.8%)
Eltrombopag 50 mg QD—16/135 (11.9%)120/135 (88.9%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventPlaceboEltrombopag 50 mg QD
CataractEye disorders2/612/135
HeadacheNervous system disorders0/613/135
Cataract subcapsularEye disorders1/610/135
Retinal haemorrhageEye disorders1/610/135
Brain stem haemorrhageNervous system disorders1/610/135
Alanine aminotransferase (ALT) increasedInvestigations1/611/135
Heart rate increasedInvestigations1/610/135
Renal function test abnormalInvestigations1/610/135
Gastrointestinal haemorrhageGastrointestinal disorders1/610/135
CellulitisInfections and infestations1/610/135
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPlaceboEltrombopag 50 mg QD
HeadacheNervous system disorders20/6140/135
NasopharyngitisInfections and infestations12/6114/135
FatigueGeneral disorders8/6113/135
DiarrhoeaGastrointestinal disorders6/6117/135
NauseaGastrointestinal disorders4/6117/135
Upper respiratory tract infectionInfections and infestations7/6114/135
DizzinessNervous system disorders6/615/135
ConstipationGastrointestinal disorders6/616/135
Pain in extremityMusculoskeletal and connective tissue disorders6/619/135
Oedema peripheralGeneral disorders6/612/135

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboEltrombopag 50 mg QDTotal
Mean51.0 ± 14.7246.5 ± 15.6147.9 ± 15.45
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEltrombopag 50 mg QDTotal
Female4393136
Male194261
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboEltrombopag 50 mg QDTotal
African American/African123
American Indian/Alaska native4812
East Asian101929
South-East Asian325
Native Hawaiian or other Pacific Islander011
White/Arabic/North African268
White/Caucasian/European4295137
Mixed Race022
Stratification variable
Stratification variable(Participants)PlaceboEltrombopag 50 mg QDTotal
Use of ITP medication at randomization316394
Splenectomy at randomization215071
Platelet count less or equal 15,000 per microliter306797
09

Study locations

115 sites
  • GSK Investigational Site
    Duarte, California 91010, United States
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    San Francisco, California 94143, United States
  • GSK Investigational Site
    Washington, District of Columbia 20007, United States
  • GSK Investigational Site
    Washington, District of Columbia 20010-2975, United States
  • GSK Investigational Site
    Hollywood, Florida 33021, United States
  • GSK Investigational Site
    Atlanta, Georgia 30341, United States
  • GSK Investigational Site
    Savannah, Georgia 31405, United States
  • GSK Investigational Site
    Honolulu, Hawaii 96813, United States
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    Worcester, Massachusetts 01655, United States
  • GSK Investigational Site
    St. Louis, Missouri 63110, United States
  • GSK Investigational Site
    Buffalo, New York 14215, United States
  • GSK Investigational Site
    New York, New York 10029, United States
  • GSK Investigational Site
    New York, New York 10065, United States
  • GSK Investigational Site
    Cleveland, Ohio 44106, United States
  • GSK Investigational Site
    Lawton, Oklahoma 73505, United States
  • GSK Investigational Site
    Portland, Oregon 97227, United States
  • GSK Investigational Site
    Willow Grove, Pennsylvania 19090, United States
  • GSK Investigational Site
    Dallas, Texas 75137, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Lubbock, Texas 79410, United States
  • GSK Investigational Site
    Lubbock, Texas 79415, United States
  • GSK Investigational Site
    Arlington, Virginia 22205, United States
  • GSK Investigational Site
    Seattle, Washington 98109, United States
  • GSK Investigational Site
    Tacoma, Washington 98405, United States
  • GSK Investigational Site
    Vienna, A-1090, Austria
  • GSK Investigational Site
    Burnaby, British Columbia V5H 4K7, Canada
  • GSK Investigational Site
    Saint John's, Newfoundland and Labrador A1B 3V6, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8N 3Z5, Canada
  • GSK Investigational Site
    Weston, Ontario M9N 1N8, Canada
  • GSK Investigational Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • GSK Investigational Site
    Laval, Quebec H7M 3L9, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4M1, Canada
  • GSK Investigational Site
    Montreal, Quebec H3T 1E2, Canada
  • GSK Investigational Site
    Jiang Su Province, 215006, China
  • GSK Investigational Site
    Shanghai, 200025, China
  • GSK Investigational Site
    Tianjin, 300020, China
  • GSK Investigational Site
    Brno, 625 00, Czech Republic
  • GSK Investigational Site
    Hradec Kralove, 500 05, Czech Republic
  • GSK Investigational Site
    Olomouc, 775 20, Czech Republic
  • GSK Investigational Site
    Praha 2, 128 20, Czech Republic
  • GSK Investigational Site
    Odense, 5000, Denmark
  • GSK Investigational Site
    Kuopio, 70210, Finland
  • GSK Investigational Site
    Bobigny, 93003, France
  • GSK Investigational Site
    Caen, 14033, France
  • GSK Investigational Site
    Créteil, 94010, France
  • GSK Investigational Site
    Pessac, 33604, France
  • GSK Investigational Site
    Muenchen, Bayern 80639, Germany
  • GSK Investigational Site
    Giessen, Hessen 35392, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30625, Germany
  • GSK Investigational Site
    Saarbruecken, Saarland 66113, Germany
  • GSK Investigational Site
    Berlin, 13353, Germany
  • GSK Investigational Site
    Athens, 10676, Greece
  • GSK Investigational Site
    Athens, 11527, Greece
  • GSK Investigational Site
    Athens, 15123, Greece
  • GSK Investigational Site
    Heraklion, Crete, 71201, Greece
  • GSK Investigational Site
    Thessaloniki, 57010, Greece
  • GSK Investigational Site
    Shatin, Hong Kong
  • GSK Investigational Site
    Bangalore, 560002, India
  • GSK Investigational Site
    Manipal, 576 104, India
  • GSK Investigational Site
    Napoli, Campania 80131, Italy
  • GSK Investigational Site
    Bologna, Emilia-Romagna 40138, Italy
  • GSK Investigational Site
    Albano Laziale (Roma), Lazio 00041, Italy
  • GSK Investigational Site
    Milano, Lombardia 20132, Italy
  • GSK Investigational Site
    Padova, Veneto 35128, Italy
  • GSK Investigational Site
    Vicenza, Veneto 36100, Italy
  • GSK Investigational Site
    Amersfoort, 3816 CP, Netherlands
  • GSK Investigational Site
    Nijmegen, 6525 GA, Netherlands
  • GSK Investigational Site
    Zwolle, 8025 AB, Netherlands
  • GSK Investigational Site
    Auckland, 1309, New Zealand
  • GSK Investigational Site
    Auckland, 1701, New Zealand
  • GSK Investigational Site
    Christchurch, 8011, New Zealand
  • GSK Investigational Site
    Grafton, 1003, New Zealand
  • GSK Investigational Site
    Lima, Lima 27, Peru
  • GSK Investigational Site
    Lima, Lima 41, Peru
  • GSK Investigational Site
    Gdansk, 80-952, Poland
  • GSK Investigational Site
    Krakow, 31-501, Poland
  • GSK Investigational Site
    Legnica, 59-200, Poland
  • GSK Investigational Site
    Opole, 45-372, Poland
  • GSK Investigational Site
    Slupsk, 76-200, Poland
  • GSK Investigational Site
    Torun, 87-100, Poland
  • GSK Investigational Site
    Wroclaw, 50-367, Poland
  • GSK Investigational Site
    Moscow, 125167, Russian Federation
  • GSK Investigational Site
    Novosibirsk, 630087, Russian Federation
  • GSK Investigational Site
    St Petersburg, 193024, Russian Federation
  • GSK Investigational Site
    Kosice, 041 90, Slovakia
  • GSK Investigational Site
    Martin, 036 59, Slovakia
  • GSK Investigational Site
    Presov, 080 01, Slovakia
  • GSK Investigational Site
    Madrid, 28006, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Palma de Mallorca, 07014, Spain
  • GSK Investigational Site
    Taipei, 100, Taiwan
  • GSK Investigational Site
    Taipei, 110, Taiwan
  • GSK Investigational Site
    Taipei, 114, Taiwan
  • GSK Investigational Site
    Taipei, Taiwan
  • GSK Investigational Site
    Sfax, 3029, Tunisia
  • GSK Investigational Site
    Sousse, 4000, Tunisia
  • GSK Investigational Site
    Tunis, 1008, Tunisia
  • GSK Investigational Site
    Dnipropetrovsk, 49102, Ukraine

Showing the first 100 of 115 sites across 25 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011 Jan 29;377(9763):393-402. doi: 10.1016/S0140-6736(10)60959-2. Epub 2010 Aug 23. Erratum In: Lancet. 2011 Jan 29;377(9763):382. PubMed 20739054 ↗
  • Haselboeck J, Pabinger I, Ay C, Koder S, Panzer S. Platelet activation and function during eltrombopag treatment in immune thrombocytopenia. Ann Hematol. 2012 Jan;91(1):109-13. doi: 10.1007/s00277-011-1249-5. Epub 2011 May 7. PubMed 21553010 ↗
  • Hayes S, Ouellet D, Zhang J, Wire MB, Gibiansky E. Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing. J Clin Pharmacol. 2011 Oct;51(10):1403-17. doi: 10.1177/0091270010383019. Epub 2010 Dec 8. PubMed 21148042 ↗
  • Tarantino MD, Fogarty P, Mayer B, Vasey SY, Brainsky A. Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagul Fibrinolysis. 2013 Apr;24(3):284-96. doi: 10.1097/MBC.0b013e32835fac99. PubMed 23492914 ↗
  • Fogarty PF, Tarantino MD, Brainsky A, Signorovitch J, Grotzinger KM. Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia. Curr Med Res Opin. 2012 Jan;28(1):79-87. doi: 10.1185/03007995.2011.644849. Epub 2011 Dec 20. PubMed 22117897 ↗
  • Signorovitch J, Brainsky A, Grotzinger KM. Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia. Qual Life Res. 2011 Dec;20(10):1737-44. doi: 10.1007/s11136-011-9912-9. Epub 2011 May 1. PubMed 21533818 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2006
First posted
Aug 31, 2006
Start
Nov 2006
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results first posted
Feb 23, 2010
Last update
Apr 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00370331
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 31, 2006
Start date
Nov 2006
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Feb 23, 2010
Last update
Apr 18, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion